Search results for "Venous thromboembolism"
MKSAP Quiz: Risks of gender dysphoria treatment
A 37-year-old transgender woman (genetic male, identifies as a female) requests feminizing hormone therapy. She was diagnosed with gender dysphoria by her psychiatrist in accordance with DSM-5 criteria. Following lab studies, what treatment risks should be reviewed with the patient?
https://acpinternist.org/weekly/archives/2023/06/06/3.htm
6 Jun 2023
Managing DOACs in primary care
Primary care physicians play a crucial role in ongoing anticoagulation management, including educating patients about the signs of venous thromboembolism.
https://acpinternist.org/archives/2022/04/managing-doacs-in-primary-care.htm
1 Apr 2022
Patients with provoked VTE often on anticoagulation longer than recommended
Three variables were associated with receiving anticoagulation for longer than three months after a provoked venous thromboembolism (VTE): direct oral anticoagulant use, history of VTE, and history of myocardial infarction.
https://acpinternist.org/weekly/archives/2022/11/01/4.htm
1 Nov 2022
New resource offers pearls for perioperative medicine
A recent book addresses perioperative medicine, including how to be a perioperative consultant, prophylaxis for venous thromboembolism, coexisting medical problems, and common postoperative complications.
https://acpinternist.org/archives/2022/02/new-resource-offers-pearls-for-perioperative-medicine.htm
1 Feb 2022
MKSAP Quiz: Evaluation for β-thalassemia intermedia
A 35-year-old man is evaluated during a routine visit for β-thalassemia intermedia. One year ago, he began requiring erythrocyte transfusions every 4 to 6 months for symptomatic anemia. He has no other symptoms or medical problems, and his only medication is folic acid. Following a physical exam and lab studies, what is the most appropriate additional management?
https://acpinternist.org/weekly/archives/2023/09/12/3.htm
12 Sep 2023
Apixaban shows superior effectiveness, safety compared to rivaroxaban
For patients with venous thromboembolism, initiation of apixaban was associated with lower rates of recurrence and intracranial and gastrointestinal bleeding than rivaroxaban in a population-based cohort study.
https://acpinternist.org/weekly/archives/2021/12/07/2.htm
7 Dec 2021
Pros, cons of prolonged anticoagulation after a clot
Experts debate about provoked vs. unprovoked venous thromboembolism, and whether a once-high-risk patient can have that status removed later.
https://acpinternist.org/archives/2020/02/pros-cons-of-prolonged-anticoagulation-after-a-clot.htm
1 Feb 2020
DOACs may be safe, effective for VTE prevention in patients with higher weight, BMI
Patients with first-time venous thromboembolism (VTE) who weighed 120 kg or more and had a body mass index (BMI) of 40 kg/m2 or more were not at higher risk for bleeding or recurrent VTE with direct-acting oral anticoagulants (DOACs) versus warfarin.
https://acpinternist.org/weekly/archives/2021/11/09/4.htm
9 Nov 2021
Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine
Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
https://acpinternist.org/weekly/archives/2022/08/23/4.htm
23 Aug 2022
New warning for testosterone, approval for inhaled insulin
This update covers a revised warning on testosterone products about the risk of venous thromboembolism, and approval of a fast-acting inhaled insulin to treat diabetes in adults.
https://acpinternist.org/archives/2014/09/fda.htm
1 Sep 2014